- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- May 2024
- 138 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 140 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 133 Pages
Global
From €5915EUR$6,499USD£5,024GBP
Nutropin is a recombinant human growth hormone (rhGH) used to treat endocrine and metabolic disorders. It is used to treat growth failure in children and adults due to inadequate secretion of endogenous growth hormone, as well as growth hormone deficiency due to genetic causes, radiation therapy, or trauma. It is also used to treat short stature associated with Turner syndrome, Prader-Willi syndrome, and chronic renal insufficiency. Nutropin is administered via subcutaneous injection and is available in a variety of dosage forms.
Nutropin is a widely used drug in the endocrine and metabolic disorders market. It is used to treat a variety of conditions, including growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, and chronic renal insufficiency. It is also used to treat short stature associated with these conditions.
Companies in the Nutropin market include Genentech, Novo Nordisk, Eli Lilly, Pfizer, and Merck. Show Less Read more